Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership89,184 shares
Latest Disclosed Value $ 11,749,100
D. E. Shaw & Co., Inc. ownership in NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 89,184 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $11,749,100 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 14, 2025 disclosing 0 shares of Neurocrine Biosciences, Inc.. The current value of the position is $14,725,170 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (NBIX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

NBIX / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 89,184 89,184 11,749 0.0052
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -14,592 -100.00 0 -100.00
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,592 -14,118 -49.17 1,614 -58.83 0.0014
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,710 -140,744 -83.06 3,919 -79.93 0.0029
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 169,454 61,076 56.35 19,524 30.86 0.0168
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 108,378 -36,902 -25.40 14,920 -25.54 0.0140
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 145,280 69,278 91.15 20,037 100.09 0.0171
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 76,002 16,940 28.68 10,014 50.72 0.0088
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 59,062 -181,422 -75.44 6,644 -70.70 0.0069
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 240,484 61,378 34.27 22,678 25.09 0.0232
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 179,106 -79,937 -30.86 18,129 -41.41 0.0194
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 259,043 119,781 86.01 30,940 109.18 0.0342
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 139,262 -80,475 -36.62 14,791 -30.95 0.0177
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 219,737 -1,196 -0.54 21,420 3.42 0.0251
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 220,933 122,957 125.50 20,712 148.20 0.0194
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 97,976 97,976 8,345 0.0069
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -8,732 -100.00 0 -100.00
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,732 -1,148 -11.62 849 -10.35 0.0008
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,880 -109,285 -91.71 947 -91.74 0.0008
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 119,165 -89,040 -42.77 11,458 -54.89 0.0117
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 208,205 61,371 41.80 25,401 99.88 0.0303
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 146,834 17,523 13.55 12,708 -8.58 0.0198
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 129,311 -75,062 -36.73 13,900 -24.52 0.0159
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 204,373 -113,278 -35.66 18,416 -31.33 0.0227
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 317,651 158,367 99.42 26,820 91.12 0.0334
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 159,284 -51,239 -24.34 14,033 -6.65 0.0181
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 210,523 -22,942 -9.83 15,033 -47.63 0.0207
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 233,465 16,462 7.59 28,705 34.65 0.0345
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 217,003 66,656 44.33 21,319 70.99 0.0278
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 150,347 44,267 41.73 12,468 51.48 0.0170
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 106,080 101,804 2,380.82 8,231 3,041.60 0.0113
2017-11-14 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,276 4,276 262 0.0004
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -22,114 -100.00 0 -100.00
2017-05-15 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,114 -147,281 -86.95 958 -85.39 0.0017
2017-02-14 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 169,395 -12,276 -6.76 6,555 -28.74 0.0111
2016-11-14 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 181,671 146,220 412.46 9,199 470.66 0.0162
2016-08-15 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 35,451 6,541 22.63 1,612 41.03 0.0030
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,910 -284,557 -90.78 1,143 -93.55 0.0021
2016-02-16 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 313,467 -161,085 -33.94 17,733 -6.09 0.0264
2015-11-16 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 474,552 227,951 92.44 18,882 60.33 0.0278
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 246,601 -50,691 -17.05 11,777 -0.24 0.0175
2015-05-15 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 297,292 -72,178 -19.54 11,805 43.02 0.0181
2015-02-17 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 369,470 73,568 24.86 8,254 78.04 0.0106
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 295,902 172,408 139.61 4,636 152.92 0.0060
2014-08-14 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 123,494 75,895 159.45 1,833 139.30 0.0025
2014-05-15 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 47,599 20,599 76.29 766 203.97 0.0011
2014-02-14 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,000 27,000 -69.51 252 -78.73 0.0003
2013-11-20 2013-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 0 -88,550 -100.00 0 -100.00
2013-08-14 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 88,550 88,550 1,185 0.0022
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM Call 10,000 0.00 1,230 25.25 n/a n/a n/a
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM Call 10,000 982 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM Put 20,000 1,923 n/a n/a n/a
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM Put 18,700 1,618 n/a n/a n/a
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM Put 10,000 0.00 982 18.46 n/a n/a n/a
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM Put 10,000 829 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.